Supplementary tables: Real-world association of HER2/ERBB2 concordance with trastuzumab clinical benefit in advanced esophagogastric cancer.docx

Supplementary table 1a: Versions of genomic sequencing
and genes included (FoundationOne Version 1)
Supplementary
table 1b: Versions of genomic sequencing and genes included (FoundationOne
Version 2)
Supplementary
table 1c: FoundationOne CDx (Version 3)
Supplemental
table 2: Detailed patient selection criteria
Supplemental
table 3: Patients with an unknown or indeterminate HER2 test results who met
all other study inclusion criteria
Supplemental
table 4: First line anti-HER2 therapy regimens in HER2+ patients stratified
by ERBB2 amplification status
Supplemental
table 5: Demographics and clinical characteristics of patients with HER2+
tumors who received first-line trastuzumab therapy
Supplemental
table 6: Concurrent genomic alterations
Supplemental
table 7: Distribution of ISH results for patients classified by IHC status
(with positive ISH confirmation) (n = 59), by ERBB2 Amp
Supplemental
table 8: Adjusted clinical outcomes for 1L trastuzumab in patients whose
tumors were clinically HER2+, adjusting for IHC status (n=142)
Supplemental
table 9: Adjusted clinical outcomes for 1L trastuzumab in patients by
adjusting for <i>KRAS</i> status (n=142)